Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00647777 · ClinicalTrials.gov registry record · Phase 1

Food Study of Olanzapine Tablets 5 mg and Zyprexa® Tablets 5 mg

A Phase 1 study, sponsored by Mylan Pharmaceuticals.

Completed
Registry status
Phase 1
Development phase
32
Enrollment target

NCT00647777 is a Phase 1 study that has completed, run by Mylan Pharmaceuticals. The registered enrollment target is 32 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00647777, a Phase 1 study, has completed, sponsored by Mylan Pharmaceuticals.

COMPLETED
Registry status
Phase 1
Development phase
32 participants
Enrollment target

Study Summary

The objective of this study was to investigate the bioequivalence of Mylan olanzapine 5 mg tablets to Eli Lilly's Zyprexa® 5 mg tablets following a single, oral 5 mg (1 x 5 mg) dose administered under fed conditions.

Interventions

  • DRUG Olanzapine Tablets 5 mg
  • DRUG Zyprexa® Tablets 5 mg

Trial Details

FieldValue
Enrollment Target 32 participants
Start Date 2003-06
Est. Completion 2003-07
Phase Phase 1

Sponsor

Mylan Pharmaceuticals

146 total trials

What the Registry Record Tells You About NCT00647777

The ClinicalTrials.gov registry entry for NCT00647777 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mylan Pharmaceuticals, which has 146 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Olanzapine Tablets 5 mg is the first listed.

NCT00647777 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00647777 about?

NCT00647777 is a clinical study titled "Food Study of Olanzapine Tablets 5 mg and Zyprexa® Tablets 5 mg". The objective of this study was to investigate the bioequivalence of Mylan olanzapine 5 mg tablets to Eli Lilly's Zyprexa® 5 mg tablets following a single, oral 5 mg (1 x 5 mg) dose administered under fed conditions.

What is the current status of trial NCT00647777?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2003-06. Estimated completion is 2003-07.

What interventions are being tested in trial NCT00647777?

The interventions under investigation include: Olanzapine Tablets 5 mg (DRUG), Zyprexa® Tablets 5 mg (DRUG).

Who is sponsoring clinical trial NCT00647777?

This trial is sponsored by Mylan Pharmaceuticals, which has 146 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.